Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026
Company Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Fineline Cube Jul 30, 2026
Company Drug

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Fineline Cube Jul 30, 2026
Company Deals

Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project

Fineline Cube Jul 19, 2023

This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN),...

Company Deals

Sumitomo Pharma to Invest $30 Million in China for New Product Development

Fineline Cube Jul 19, 2023

Japan-based Sumitomo Pharma (TYO: 4506), through its China unit, is planning a significant investment of...

Company Drug

Antengene Initiates Phase I ERASER Study for ATG-017 in Combination with Nivolumab

Fineline Cube Jul 19, 2023

China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced the first patient dosing in...

Company Drug

Sichuan Huiyu Pharmaceutical’s KRAS G12C Drug HYP-2090PTSA Accepted for NMPA Review

Fineline Cube Jul 19, 2023

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that the...

Company Deals Medical Device

Puncture Robotic Secures $13.9 Million in Series A+ Funding to Advance Medical Robotics

Fineline Cube Jul 19, 2023

Puncture Robotic, a Shanghai-based developer of medical robots, has reportedly raised RMB 100 million (USD...

Company Drug

Sanofi and AstraZeneca Receive FDA Approval for RSV Prevention Treatment Beyfortus

Fineline Cube Jul 18, 2023

France-based Sanofi (NASDAQ: SNY) has announced that it, along with AstraZeneca (AZ; NASDAQ: AZN), has...

Drug Policy / Regulatory

NMPA Releases 70th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jul 18, 2023

The National Medical Products Administration (NMPA) has released the 70th batch of reference drugs for...

Company Deals

Cutia Therapeutics’ CU-40101 Completes Phase I Clinical Trial for Androgenetic Alopecia

Fineline Cube Jul 18, 2023

Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced the completion of the...

Company Drug

Mabwell Bioscience’s 7MW3711 ADC for B7-H3 Gets Clinical Trial Approval in China

Fineline Cube Jul 18, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical...

Company Drug

Bayer’s Kerendia Officially Launched in China for Type 2 Diabetes-Related CKD

Fineline Cube Jul 18, 2023

German pharmaceutical giant Bayer’s (ETR: BAYN) Kerendia (finerenone), the first nonsteroidal, selective mineralocorticoid receptor (MR)...

Company Deals

Sensview Secures Tens of Millions in Series A+ Funding for X-Ray Detector Tech

Fineline Cube Jul 18, 2023

Sensview, a developer of solid-state imaging chips and detector module products based in Chengdu, has...

Company Deals

Nanjing Enrui Kainuo Biotechnology Secures Pre-Series A Funding for Cell Therapy Development

Fineline Cube Jul 18, 2023

Nanjing Enrui Kainuo Biotechnology Co., Ltd, a China-based cell therapy developer, has reportedly raised tens...

Company Drug

Shenzhen Salubris Pharmaceuticals Receives FDA Clearance for SAL0119 Clinical Trial

Fineline Cube Jul 18, 2023

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, has announced that it...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for CTLA-4 and PD-1 Inhibitor Combo Study

Fineline Cube Jul 18, 2023

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that it has received approval from China’s...

Company Drug

Shanghai Pharmaceuticals Gets NMPA Green Light for Recombinant Human Adenovirus Type 5 Trial

Fineline Cube Jul 18, 2023

Shanghai Pharmaceuticals (HKG: 2607; SHA: 601607), a leading pharmaceutical company in China, has announced that...

Policy / Regulatory

China’s NHC Issues Guidelines to Enhance Clinical Department Capacities for Serious Diseases

Fineline Cube Jul 18, 2023

The National Health Commission (NHC) has issued a set of guidelines aimed at strengthening clinical...

Company Drug

Nanjing Immunophage Biotech’s IPG11406 Approved for SLE Clinical Trial in China

Fineline Cube Jul 18, 2023

Nanjing Immunophage Biotech Co., Ltd, a China-based biotechnology company, has announced that it has received...

Company Deals

Pyrotech (Beijing) Biotechnology Secures $97.37 Million in Series A Financing

Fineline Cube Jul 18, 2023

China-based biotech firm Pyrotech (Beijing) Biotechnology Co., Ltd announced the successful completion of a CNY...

Company

Shanghai Henlius Biotech Announces Executive Leadership Changes

Fineline Cube Jul 18, 2023

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced significant changes in its executive leadership....

Company Drug

Zai Lab and argenx Report Positive Preliminary Results from Vyvgart Hytrulo CIDP Study

Fineline Cube Jul 18, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its Netherlands-based partner argenx SE (NASDAQ:...

Posts pagination

1 … 537 538 539 … 701

Recent updates

  • Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease
  • Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements
  • Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression
  • Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares
  • CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Company Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Company Drug

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Company Drug

Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.